CalciMedica Announces First Patient Enrolled In International Expansion Of CARPO Trial Of Auxora In Acute Pancreatitis
Portfolio Pulse from Benzinga Newsdesk
CalciMedica has announced the enrollment of the first patient in the international expansion of its CARPO trial of Auxora in acute pancreatitis. The trial is expected to enroll patients in over 30 sites in the US and India, with top-line data expected in the first half of 2024.
August 09, 2023 | 11:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CalciMedica's stock may be impacted by the news of the international expansion of its CARPO trial of Auxora. The trial's success could potentially boost the company's stock.
The news directly pertains to CalciMedica's ongoing clinical trial, which is a significant aspect of the company's operations. The success of the trial could potentially lead to regulatory approval and commercialization of the drug, positively impacting the company's revenues and stock price. However, as the top-line data is expected in 2024, the immediate impact on the stock price may be neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100